Interim Report January – June 2015


STRONG GROWTH AND ROLLING 12 MONTHS SALES ABOVE SEK 100 MILLION
SECOND QUARTER 2015 (APR – JUN)

 • Net sales in the quarter amounted to SEK 29.1 (18.5) million, corresponding
to an increase of 58 percent.
• Operating income before depreciation and amortization (EBITDA) amounted to SEK
4.3 (1.8) million, corresponding to an EBITDA margin of 15 percent.
• Net income amounted to SEK 1.3 (0.8) million, resulting in earnings per share
of SEK 0.06 (0.04). The figures are affected by amortization and depreciation of
SEK 2.8 (0.4) million.
• Cash flow from operating activities was SEK 8.8 (0.8) million.
• Net sales of non-Durable goods* in the quarter amounted to SEK 27.4 (18.5)
million, corresponding to an increase of 48 percent in SEK. Sales of non-Durable
goods increased by 26 percent in local currency.
• Products for warm perfusion (STEEN Solution™ and products related to the use
of the XPS™) accounted for 35 (23) percent of total sales of non-Durable goods.
In total, products for warm perfusion and the XPS™ accounted for 39 (23) percent
of total sales.
• During the quarter rolling 12 month sales amounted to SEK 108.9 million and
were above SEK 100 million for the first time.
• XVIVO Perfusion’s share warrant program 2015/2017, which was offered to
employees, was fully subscribed.

THE PERIOD 2015 (JAN – JUN)

 • Net sales in the period amounted to SEK 60.9 (26.7) million, corresponding to
an increase of 66 percent.
• Operating income before depreciation and amortization (EBITDA) excluding one
-time expenses amounted to SEK 8.8 (6.1) million, corresponding to an EBITDA
margin of 14 percent. One-time expenses of SEK 1.7 (1.3) million related to the
dispute regarding three Vivoline patents/patent applications have been charged
against the period. Operating income before depreciation and amortization
(EBITDA) amounted to SEK 7.2 (4.9) million, corresponding to an EBITDA margin of
12 percent.
• Net income amounted to SEK 0.3 (2.6) million, resulting in earnings per share
of SEK 0.01 (0.13). The figures are affected by amortization and depreciation of
5.7 (0.7) million.
• Cash flow from operating activities was SEK 2.9 (-2.6) million.
• Net sales of non-Durable goods* in the period amounted to SEK 52.5 (36.7)
million, corresponding to an increase of 43 percent in SEK. Sales of non-Durable
goods increased by 22 percent in local currency.
• Products for warm perfusion (STEEN Solution™ and products related to the use
of the XPS™) accounted for 33 (24) percent of total sales of non-Durable goods.
In total, products for warm perfusion and the XPS™ accounted for 42 (24) percent
of total sales.
• XVIVO Perfusion and Vivoline have reached an agreement whereby, amongst other
things, XVIVO Perfusion withdraws its claim at Lund District Court and
compensates Vivoline for trial costs. Through this agreement, the parties'
differences in regard to the dispute have been definitively settled.
• XVIVO Perfusion has received TGA approval of XPS™ (Xvivo Perfusion System).
This enables sales of XPS™ in Australia.
• The United States Patent and Trademark Office (USPTO) has approved a third
patent in the “Preservation and evaluation solution” family.  This means that
STEEN Solution™ has broader patent protection in the USA.

SIGNIFICANT EVENTS AFTER THE END OF THE QUARTER

• Two XPS™ contracts were signed after the end of the quarter. When the report
was published 21 clinics have access to the XPS™, of which 18 are located in the
US.
• The first clinical liver transplant with a liver perfused with STEEN Solution™
was performed in Toronto, Canada. In total three successful liver transplants
have been performed as part of a phase 1 clinical trial.
• The company has taken a policy decision to apply for a listing on Nasdaq
Stockholm’s main list during 2016. This will entail one-time expenses for the
company which will be recognized and reported on an ongoing basis during the
coming year.

CONFERENCE CALL

CEO Magnus Nilsson will present the report in a conference call at 2 p.m. CET on
Thursday, August 13, 2015. Telephone: +44 (0) 1452 555566, enter code 59833055.

August 13, 2015
Gothenburg
XVIVO Perfusion AB (publ)
Magnus Nilsson, CEO

* Durable goods are sales revenues from the XPS™.
For further information please contact:
Christoffer Rosenblad, CFO, +46 31 788 21 59,
christoffer.rosenblad@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the
company’s website, www.xvivoperfusion.com

The information was submitted for publication on August 13, 2015 at 8:30 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB is a medical technology company which develops solutions and
systems for assessing and preserving organs outside the body and for selecting
usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the
USA. The XVIVO share is listed on NASDAQ OMX First North and has the ticker
symbol XVIVO. More information can be found on the website
www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity
number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com

Attachments

08122295.pdf